In combination with - in cancer therapy successfully tested - JAK inhibitors ruxolitinib (JAK1/2 inhibitor) and tofacitinib (JAK1/3 inhibitor), additional treatment success with resolution of enteropathy and respiratory function was achieved in five of eight patients. Here, JAK1 is linked to Abnormal intestine morphology.